SCHEMBL1899359

SCHEMBL1899359

CC(C)(C)OC(=O)N1C[C@@H](CO)c2c1cc(OCc1ccccc1)c1ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 4/20 0.40
TLR7 Q9NYK1 2/20 0.40
CCR8 P51685 1/20 0.37
YAP1 P46937 3/20 0.37
GHSR Q92847 1/20 0.37
NPC1 O15118 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36
TACR1 P25103 2/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
ADH1A P07327 1/20 0.35
KIT P10721 1/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
ABL2 P42684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325760 1.00 TLR9 (0.40) TLR9TLR7CCR8YAP1GHSR
SCHEMBL13060966 0.92 TLR9 (0.40) TLR9TLR7CCR8YAP1GHSR
SCHEMBL13007045 0.92 TLR9 (0.40) TLR9TLR7CCR8YAP1GHSR
SCHEMBL13311246 0.91 ADH1A (0.45) TLR9TLR7CCR8YAP1GHSR
SCHEMBL12529896 0.91 ADH1A (0.45) TLR9TLR7CCR8YAP1GHSR
SCHEMBL14037334 0.91 ADH1A (0.45) TLR9TLR7CCR8YAP1GHSR
SCHEMBL14527518 0.91 TLR9 (0.40) TLR9TLR7CCR8YAP1GHSR
SCHEMBL16486870 0.91 ADH1A (0.45) TLR9TLR7CCR8YAP1GHSR
SCHEMBL8318149 0.90 TLR9 (0.42) TLR9TLR7YAP1GHSRPDE4A
SCHEMBL12154968 0.90 TLR9 (0.39) TLR9TLR7CCR8YAP1GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4633738-A1 CYTOTOXIC COMPOUNDS Pheon Therapeutics Ltd (GB) 2025-10-22 EP disclosed
WO-2024127332-A1 CYTOTOXIC COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2024-06-20 WO disclosed
US-20240002379-A1 ASYMMETRIC CONJUGATE COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2024-01-04 US disclosed
US-20230302142-A1 Cytotoxic Agents Pheon Therapeutics Ltd. (GB) 2023-09-28 US disclosed
US-20230302142-A1 Cytotoxic Agents Pheon Therapeutics Ltd. (GB) 2023-09-28 US disclosed
US-20220098191-A1 G-A CROSSLINKING CYTOTOXIC AGENTS Pheon Therapeutics Ltd. (GB) 2022-03-31 US disclosed
WO-2020157491-A1 G-A CROSSLINKING CYTOTOXIC AGENTS FEMTOGENIX LIMITED (GB) 2020-08-06 WO disclosed
US-20190144443-A1 ASYMMETRIC CONJUGATE COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2019-05-16 US disclosed
WO-2011054837-A2 BIFUNCTIONAL PRODRUGS AND DRUGS GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENLICHEN RECHTS (DE) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098191-A1 G-A CROSSLINKING CYTOTOXIC AGENTS CCNA1, GNA15, RPS26 TLR9 4053/4885TLR7 4036/4885CCR8 2141/4885
US-20240002379-A1 ASYMMETRIC CONJUGATE COMPOUNDS TUBA1C, MTX2, CCNO TLR9 1007/4885TLR7 715/4885CCR8 23/4885
US-20190144443-A1 ASYMMETRIC CONJUGATE COMPOUNDS TUBA1C, MTX2, CCNO TLR9 994/4885TLR7 721/4885CCR8 23/4885
US-20230302142-A1 Cytotoxic Agents ANXA11, ANXA5, HAX1 TLR9 857/4885TLR7 1294/4885CCR8 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.